Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Metrics to compare | NWRN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNWRNPeersSector | |
---|---|---|---|---|
P/E Ratio | 9.9x | −1.2x | −0.5x | |
PEG Ratio | 0.05 | 0.15 | 0.00 | |
Price/Book | 107.5x | 0.1x | 2.6x | |
Price / LTM Sales | 3.0x | 3.0x | 3.3x | |
Upside (Analyst Target) | 163.5% | 91.2% | 40.3% | |
Fair Value Upside | Unlock | 3.6% | 4.7% | Unlock |